T. Mason

SGLT2 Inhibition with Empagliflozin Increases Circulating Provascular Progenitor Cells in People with Type 2 Diabetes Mellitus.

Deepak L. Bhatt, Lawrence A Leiter, B. Zinman, 2019, Cell metabolism.

Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.

Deepak L. Bhatt, Lawrence A Leiter, B. Zinman, 2019, Circulation.

Effect of Empagliflozin on Left Ventricular Mass in Patients with Type 2 Diabetes and Coronary Artery Disease: The EMPA-HEART CardioLink-6 Randomized Clinical Trial.

Deepak L. Bhatt, Lawrence A Leiter, B. Zinman, 2019, Circulation.

Empagliflozin Reduces Myocardial Extracellular Volume in Patients With Type 2 Diabetes and Coronary Artery Disease.

Lawrence A Leiter, B. Zinman, S. Verma, 2021, JACC. Cardiovascular imaging.

Empagliflozin and Left Ventricular Remodeling in People Without Diabetes: Primary Results of the EMPA-HEART 2 CardioLink-7 Randomized Clinical Trial

Deepak L. Bhatt, Lawrence A Leiter, M. Lafreniere-Roula, 2022, Circulation.